Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
19.05
-0.10 (-0.55%)
May 1, 2026, 11:40 AM EDT - Market open
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 150 employees as of December 31, 2025. The number of employees increased by 16 or 11.94% compared to the previous year.
Employees
150
Change
16
Growth
11.94%
Revenue / Employee
$824,480
Profits / Employee
-$257,507
Market Cap
1.52B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 150 | 16 | 11.94% |
| Sep 30, 2025 | 147 | 14 | 10.53% |
| Jun 30, 2025 | 142 | 13 | 10.08% |
| Mar 31, 2025 | 142 | 12 | 9.23% |
| Dec 31, 2024 | 134 | 1 | 0.75% |
| Sep 30, 2024 | 133 | 0 | - |
| Jun 30, 2024 | 129 | -4 | -3.01% |
| Mar 31, 2024 | 130 | -3 | -2.26% |
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Sep 30, 2023 | 133 | 15 | 12.71% |
| Jun 30, 2023 | 133 | 29 | 27.88% |
| Mar 31, 2023 | 133 | 38 | 40.00% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Sep 30, 2022 | 118 | 24 | 25.53% |
| Jun 30, 2022 | 104 | 21 | 25.30% |
| Mar 31, 2022 | 95 | 35 | 58.33% |
| Dec 31, 2021 | 93 | 33 | 55.00% |
| Sep 30, 2021 | 94 | - | - |
| Jun 30, 2021 | 83 | - | - |
| Mar 31, 2021 | 60 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 711 |
| Agios Pharmaceuticals | 540 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| Intellia Therapeutics | 377 |
| Wave Life Sciences | 317 |
| Nuvation Bio | 298 |
| AtaiBeckley | 99 |
GLUE News
- 11 days ago - Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors - GlobeNewsWire
- 6 weeks ago - Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 6 weeks ago - Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 7 weeks ago - Monte Rosa Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 2 months ago - Monte Rosa Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewsWire